Streetbeat News

ALPN

Alpine Immune Sciences Inc

CEO

Mitchell Gold

Employees

125

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.

Open

64.98

Mkt cap

4.5B

Volume

4.3M

High

65.00

P/E Ratio

-101.52

52-wk high

65.00

Low

64.97

Div yield

N/A

52-wk low

8.33

Enliven Therapeutics announced positive Phase 1 trial data for ELVN-001, causing a 26% surge in its stock. Alpine Immune Sciences saw a 36.6% jump after an acquisition agreement with Vertex. Janux Therapeutics' shares rose 16.8% amid sale considerations. Other notable movers include Rallybio Corporation with an 89.6% gain following a collaboration with Johnson & Johnson, and AnaptysBio, which rose 11.4% after an Overweight rating from Wells Fargo.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 2:01 pm

Vertex Pharmaceuticals Incorporated (VRTX) is set to acquire Alpine Immune Sciences Inc (ALPN) for approximately $4.9 billion, or $65 per share, in cash. This acquisition aims to expand Vertex's portfolio beyond its cystic fibrosis franchise into kidney disease treatments, with Alpine's lead molecule, povetacicept (ALPN-303), showing promise in IgA nephropathy (IgAN). The deal, expected to close in Q2 2024, aligns with Vertex's strategy of targeting diseases with high unmet need. Alpine's recent Phase 1b/2a study of povetacicept reported significant reductions in proteinuria and hematuria in IgAN patients.

Portfolio Pulse from Vandana Singh

April 11, 2024 | 1:01 pm

Wedbush analyst Robert Driscoll downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Outperform to Neutral.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:18 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Eliem Therapeutics, Rallybio, and Alpine Immune Sciences were among the top gainers, with stock prices increasing by 51.6%, 49.07%, and 36.62% respectively. On the downside, Aptevo Therapeutics led the losers with a 55.0% decline in its stock price. Other notable decliners include SILO Pharma and Acorda Therapeutics.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 12:11 pm

Wolfe Research analyst Andy Chen downgraded Alpine Immune Sciences (NASDAQ:ALPN) from Outperform to Peer Perform, indicating a change in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:02 pm

Wall Street anticipates a lower opening influenced by upcoming inflation data, central bank decisions, and Fed speeches. SPDR S&P 500 ETF Trust and Invesco QQQ ETF saw premarket declines. Analysts offer mixed views on market conditions, with some seeing buying opportunities amidst inflation concerns. Stocks like Robinhood and Alpine Immune Sciences are in focus due to an analyst downgrade and acquisition news, respectively. Economic data releases and Fed officials' speeches are also on investors' radar.

Portfolio Pulse from Shanthi Rexaline

April 11, 2024 | 11:27 am

Alpine Immune Sciences shares surged following the announcement that Vertex Pharmaceuticals has agreed to acquire the company, indicating a significant move in the biotech sector.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:11 am

RBC Capital analyst Gregory Renza downgraded Alpine Immune Sciences (ALPN) from Outperform to Sector Perform while raising the price target from $41 to $65.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 10:56 am

Rallybio Corporation shares surged 77.9% in pre-market trading following a collaboration announcement with Johnson & Johnson on therapeutics for pregnant individuals at risk of FNAIT. Other stocks also showed significant movement in pre-market trading, with notable gainers including Rent the Runway, Alpine Immune Sciences, and TuanChe Limited, among others. Conversely, Aptevo Therapeutics and Acorda Therapeutics led the pre-market losers, with significant drops due to a pipeline update and bankruptcy proceedings, respectively.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 10:14 am

Morgan Stanley analyst Michael Ulz downgraded Alpine Immune Sciences (ALPN) from Overweight to Equal-Weight but raised the price target from $47 to $65.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 9:46 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.